

## COURSE FACULTY, IAS–USA STAFF, BOARD OF DIRECTORS, AND VIRAL HEPATITIS ADVISORY BOARD FINANCIAL RELATIONSHIPS WITH COMMERCIAL ENTITIES

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, course faculty, IAS–USA Board members, Viral Hepatitis Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the previous 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity. The **ACCME defines a commercial interest** as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The **ACCME** does not consider providers of clinical service directly to patients to be **commercial interests** – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.” Below are the financial interests that faculty members of this course have had within the past 12 months as of the date listed. View the [Faculty Financial Disclosure Policy](#).

### BERKELEY, CALIFORNIA—APRIL 8, 2019

Course Chairs	
<b>Stephen E. Follansbee, MD</b> Director, HIV Services and Travel Medicine, Retired Kaiser Permanente San Francisco San Francisco, California	<i>Dr Follansbee has no relevant financial affiliations to disclose. (Updated 03/23/19)</i>
<b>Annie F. Luetkemeyer, MD</b> Associate Professor of Medicine University of California San Francisco San Francisco, California	<i>Dr Luetkemeyer has received grant support awarded to her institution from AbbVie, Gilead Sciences, Inc, Merck &amp; Co, Inc, Proteus, and ViiV Healthcare. (Updated 04/03/19)</i>
<b>Robert T. Schooley, MD</b> Professor and Vice Chair of Medicine University of California San Diego La Jolla, California	<i>Dr Schooley has served as a consultant to CytoDyn and Gilead Sciences, Inc; has received grant support from Gilead Sciences, Inc; and holds stock or stock options in Antiva Biosciences and CytoDyn. His spouse has served on advisory and data monitoring boards for GlaxoSmithKline/ViiV Healthcare and received research grants awarded to her institution from Gilead Sciences, Inc. (Updated 04/02/19)</i>
Speakers	
<b>Constance A. Benson, MD</b> Professor of Medicine University of California San Diego La Jolla, California	<i>Dr Benson has served on advisory and data monitoring boards for GlaxoSmithKline/ViiV Healthcare and received research grants awarded to her institution from Gilead Sciences, Inc. Her spouse has served as a consultant to CytoDyn and Gilead Sciences, Inc; has received grant support from Gilead Sciences, Inc; and holds stock or stock options in Antiva Biosciences and CytoDyn. (Updated 03/26/19)</i>
<b>R. Douglas Bruce, MD, MA, MS</b> Associate Clinical Professor of Medicine Yale University New Haven, Connecticut	<i>Dr Bruce has no relevant financial affiliations to disclose. (Updated 02/20/19)</i>
<b>Peter Chin-Hong, MD</b> Professor of Medicine University of California San Francisco San Francisco, California	<i>Dr Chin-Hong has received research support from Karius. (Updated 04/08/19)</i>
<b>Joseph J. Eron, Jr, MD</b> Professor of Medicine University of North Carolina Chapel Hill, North Carolina	<i>Dr Eron has served as an ad hoc consultant to Janssen, ViiV Healthcare, Merck, and Gilead Sciences, Inc. His institution receives contracts for clinical research on which Dr Eron is the local principal investigator from Janssen Therapeutics, ViiV Healthcare, and Gilead Sciences, Inc. (Updated 11/19/18)</i>
<b>Hyman Scott, MD, MPH</b> Medical Director, Clinical Research Bridge HIV San Francisco Department of Public Health San Francisco, California	<i>Dr Scott has no relevant financial affiliations to disclose. (Updated 03/26/19)</i>
IAS–USA CME Planner and Reviewer	
<b>Donna M. Jacobsen</b> Executive Director	<i>Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 04/05/19)</i>
IAS–USA Board of Directors	
The nonstaff members of the IAS–USA Board of Directors are not compensated for their roles in governing and overseeing the IAS–USA. Please see <a href="https://iasusa.org/about/ias-usa-board-of-directors/">https://iasusa.org/about/ias-usa-board-of-directors/</a> for information about board members and a link to up-to-date financial disclosure information.	
IAS–USA Viral Hepatitis Advisory Board	
The members of the IAS–USA Viral Hepatitis Advisory Board are not compensated for their roles in governing and overseeing the IAS–USA viral hepatitis educational efforts. Please see <a href="https://iasusa.org/activities/live-courses/hepatitis-c-virus-courses/viral-hepatitis-advisory-board/">https://iasusa.org/activities/live-courses/hepatitis-c-virus-courses/viral-hepatitis-advisory-board/</a> for information about the financial disclosures for the IAS–USA Viral Hepatitis Advisory Board.	